Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KALA
STRONG SELLREMOVEKALA BIO, Inc. · Healthcare · United States · $104M · Avg Vol: $291K/d
KALA BIO is a micro-cap clinical-stage biopharmaceutical company whose extremely high cash burn and binary clinical trial risk make it unsuitable for a concentrated quality fund.
COMPANY DESCRIPTION
KALA BIO, Inc. is a biopharmaceutical company focused on developing innovative therapies for rare and severe ophthalmic diseases, leveraging its proprietary product candidates. The company aims to address unmet medical needs in eye care with its lead candidate, KPI-012, which targets various ocular surface diseases with a novel secretome technology. KALA BIO is a clinical-stage biotechnology company specializing in ophthalmology, with its future growth dependent on successful clinical development and regulatory approvals for its pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| Revenue | 11M | 4M | 0 | 0 | -65.4% |
| EPS | -108.32 | -29.48 | -17.35 | -10.15 | — |
| Shares | 1M | 2M | 3M | 6M | +365.0% |
| Debt | 80M | 43M | 36M | 32M | -26.2% |
| Equity | 17M | 19M | 8M | 12M | -9.8% |
| Op CF | -108M | -79M | -28M | -29M | — |
| Inv CF | 71M | 63M | -429,000 | -208,000 | — |
| Fin CF | 43M | -8M | 9M | 30M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KALA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KALA | KALA BIO, Inc.(you) | $104M | 2 | STRONG SELL |
| INO | Inovio Pharmaceuticals, Inc. | $107M | 0 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $106M | 5 | STRONG SELL |
| CBUS | Cibus, Inc. | $117M | 3 | STRONG SELL |
| CRDF | Cardiff Oncology, Inc. | $126M | 2 | STRONG SELL |
| SGMO | Sangamo Therapeutics, Inc. | $87M | 3 | STRONG SELL |
| PEPG | PepGen Inc. | $104M | 7 | STRONG SELL |
| NTHI | NeOnc Technologies Holdings, Inc. | $125M | 1 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $86M | 3 | STRONG SELL |
| ATYR | aTyr Pharma, Inc. | $82M | 3 | STRONG SELL |
Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%